Lethal acantholytic erosive disorder
Learn about Lethal acantholytic erosive disorder, its reported features, relevant specialists, and questions to discuss at a medical consultation.
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis. Ask the treating doctor about these.
What it is
From: Orphanet
Lethal acantholytic epidermolysis bullosa is a suprabasal subtype of epidermolysis bullosa simplex (EBS) characterized by generalized oozing erosions, usually in the absence of blisters.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Abnormal dermoepidermal hemidesmosome morphology · Frequent (79-30%)
- An abnormal structure or appearance of hemidesmosomes, multiprotein complexes that facilitate the stable adhesion of basal epithelial cells to the underlying basement membrane.
- Abnormal dermoepidermal junction morphology · Frequent (79-30%)
- Any anomaly of the structure of the acellular zone that is between the dermis and the epidermis and which functions to bind the epidermis to the dermis and to serve as a selective barrier allowing the control of molecular and cellular exchanges between the two compartments.
- Absent eyebrow · Frequent (79-30%)
- Absence of the eyebrow.
- Absent eyelashes · Frequent (79-30%)
- Lack of eyelashes.
- Absent fingernail · Frequent (79-30%)
- Absence of a fingernail.
- Absent toenail · Frequent (79-30%)
- Congenital absence of the toenail.
- Acantholysis · Frequent (79-30%)
- The loss of intercellular connections, such as desmosomes, resulting in loss of cohesion between keratinocytes.
- Congenital alopecia totalis · Frequent (79-30%)
- Loss of all scalp hair with congenital onset.
- Fragile skin · Frequent (79-30%)
- Skin that splits easily with minimal injury.
- Hypovolemic shock · Frequent (79-30%)
- A state of shock characterized by decreased circulating blood volume in relation to total vascular capacity. This type of shock is characterized by a reduction of diastolic filling pressures.
- Natal tooth · Frequent (79-30%)
- A tooth present at birth or erupting within the first month of life.
- Respiratory failure · Frequent (79-30%)
- A severe form of respiratory insufficiency characterized by inadequate gas exchange such that the levels of oxygen or carbon dioxide cannot be maintained within normal limits.
- Absent hair · Frequent (79-30%)
- 2-3 finger syndactyly · Occasional (29-5%)
- A soft tissue continuity in the anteroposterior axis between the second to the third fingers that extends distally to at least the level of the proximal interphalangeal joints.
Other findings in the same source
From: Orphanet
Additional reported features include 3-4 finger syndactyly (Occasional (29-5%)); 4-5 finger syndactyly (Occasional (29-5%)); Abnormal helix morphology (Occasional (29-5%)); Abnormal pinna morphology (Occasional (29-5%)); Abnormality of the skeletal system (Occasional (29-5%)); Camptodactyly of toe (Occasional (29-5%)); Cardiomegaly (Occasional (29-5%)); Cardiomyopathy (Occasional (29-5%)); Cleft palate (Occasional (29-5%)); Clinodactyly of the 5th finger (Occasional (29-5%)). This is a selected summary, not a complete description of the condition.
When it may begin
From: Orphanet
Antenatal; Neonatal
Inheritance in the source
From: Orphanet
Autosomal recessive
Frequency and the population described
From: Orphanet
Reported case(s): 4.0; Worldwide. This is a published case count, not prevalence. Point prevalence: <1 / 1 000 000; Worldwide; Class only.
Understanding the inheritance label
From: MedlinePlus Genetics
An autosomal recessive pattern usually involves disease-causing changes in both copies of a gene. Parents may each carry one altered copy without having the condition themselves. A genetic counsellor can explain carrier testing and reproductive implications using the actual laboratory findings, rather than the condition name alone.
Which doctor should you see?
The suggested department for discussing Lethal acantholytic erosive disorder is Dermatology, with a dermatologist as the relevant type of clinician. Dermatologist; paediatric services for children as appropriate.
Additional services that may be relevant, depending on the findings, include: Clinical Genetics.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Which features of the skin, hair or nails distinguish the possibilities?
- Would photographs over time help document the changes?
- What should be expected from treatment, and how will irritation or other adverse effects be managed?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Lethal acantholytic erosive disorder. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
This condition is usually assessed by a dermatologist. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Lethal acantholytic erosive disorder — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- MedlinePlus Genetics — inheritance patterns — Public-domain Genetics education
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-1412.